Đang chuẩn bị liên kết để tải về tài liệu:
Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Vildagliptin and pioglitazone/rosiglitazone are emerging Oral Hypoglycemic Agents (OHAs) which are used to treat patients suffering from Type 2 Diabetes Mellitus (T2DM). In this analysis, we aimed to systematically compare the adverse drug events which were observed with the use of vildagliptin versus pioglitazone or rosiglitazone respectively. | Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

TÀI LIỆU LIÊN QUAN

Ebook Color atlas of pharmacology (3rd edition): Part 1

Color Atlas of Pharmacology (Part 8): Adverse Drug Effects

Adverse drug reactions in older adults: A retrospective comparative analysis of spontaneous reports to the German Federal Institute for Drugs and Medical Devices

Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011

Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib

Ebook Handbook of drugs in intensive care - An A-Z guide (5th edition): Part 1

Ebook Illustrated pharmacology for nurses: Part 1

Case Report: The risks associated with chronic theophylline therapy and measures designed to improve monitoring and management

CLINICAL PHARMACOLOGY 2003 (PART 10)
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.